DTECT v3: A Novel Platform for Detecting Dinucleotide Signatures


In recent years, genome editing technologies have made several advances that have allowed scientists to gain insight into complex genetic diseases, make progress in therapeutic development, improve crop yields, and more. However, surveillance of precise genetic changes often requires sophisticated, time-consuming, and expensive approaches such as Sanger or Next-Generation Sequencing.

Researchers at the University of Calgary have developed DTECT v3 (Dinucleotide signaTurE CapTure version 3), a robust yet simple approach that relies on the capture of targeted dinucleotide signatures. It is an all-in-one capture assay that quickly generates reliable results and requires no experimenter intervention. DTECT v3 is an invaluable platform technology for detecting various mutation types such as those introduced by CRISPR technologies, in pathogenic variants, in cancer biopsies, and more. DTECT v3 expedites the detection of genetic signatures for a fraction of the price, and significantly enhances the toolkit for precision genome editing.



  • Detection of a dinucleotide signature in a target polynucleotide:
    • Pathogens (e.g. SARS CoV-2)
    • Cancer biopsies
    • Surveillance of precision genome editing
  • Basic research
  • Clinical diagnostics
  • Crop science
  • Forensics



  • Rapid detection of dinucleotide signatures (<10 minutes).
  • Results in less time and at lower cost than sequencing.
  • Requires off-the shelf reagents and minimal equipment.
  • Internal positive and negative controls for reliable results.